Relationship between Acetylator Status and Response to Phenelzine

2015 ◽  
pp. 30-37
Author(s):  
Eve C. Johnstone
Keyword(s):  
Acetylator Status

scholarly journals Genetic characterization of N-acetyltransferase 2 variants in acquired multidrug-resistant tuberculosis in Indonesia

2021 ◽  
Author(s):  
Rika Yuliwulandari ◽  
Kinasih Prayuni ◽  
Intan Razari ◽  
Retno W Susilowati ◽  
Yenni Zulhamidah ◽  
...  
Keyword(s):  
Multidrug Resistant ◽  
Resistance Rate ◽  
Published Data ◽  
Drug Induced ◽  
Tb Treatment ◽  
Resistant Tuberculosis ◽  
Multidrug Resistant Tuberculosis ◽  
Appropriate Treatment ◽  
Acetylator Status ◽  
Mdr Tb

Background: Owing to the high resistance rate of tuberculosis (TB) to isoniazid, which is metabolized by N-acetyltransferase 2 (NAT2), we investigated the associations between NAT2 variants and multidrug-resistant (MDR)-TB. Materials & methods: The acetylator status based on NAT2 haplotypes of 128 patients with MDR-TB in Indonesia were compared with our published data from patients with anti-TB drug-induced liver injury (AT-DILI), TB and the general population. Results: NAT2*4 was more frequent in the MDR-TB group than in the AT-DILI group, TB controls and general controls. NAT2*4/*4 was significantly more frequent in patients with MDR-TB than in those with AT-DILI. NAT2*5B/7B, *6A/6A and *7B/*7B were detected at lower frequencies in patients with AT-DILI. Rapid acetylators were significantly more frequent in patients with MDR-TB than in those with AT-DILI. Conclusion: These results provide an initial data for optimizing TB treatment in the Indonesian population, and suggest that NAT2 genotyping may help to select appropriate treatment by predicting TB-treatment effect.

N-acetyltransferase (NAT) 2 acetylator status and age of onset in patients with hereditary nonpolyposis colorectal cancer (HNPCC)

2006 ◽  
Vol 241 (1) ◽  
pp. 150-157 ◽  
Author(s):  
Steffen Pistorius ◽  
Heike Görgens ◽  
Stefan Krüger ◽  
Christoph Engel ◽  
Elisabeth Mangold ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Hereditary Nonpolyposis Colorectal Cancer ◽  
Age Of Onset ◽  
Acetylator Status ◽  
Hereditary Nonpolyposis

scholarly journals Genotype-Guided Hydralazine Therapy

2020 ◽  
Vol 51 (10) ◽  
pp. 764-776 ◽  
Author(s):  
Kimberly S. Collins ◽  
Anthony L.J. Raviele ◽  
Amanda L. Elchynski ◽  
Alexander M. Woodcock ◽  
Yang Zhao ◽  
...  
Keyword(s):  
Resistant Hypertension ◽  
Antihypertensive Efficacy ◽  
Slow Acetylators ◽  
Slow Acetylator ◽  
Nat2 Genotype ◽  
Significant Relationships ◽  
Acetylator Status ◽  
Hydralazine Hydrochloride ◽  
Personalized Approach ◽  
Consistent Direction

<b><i>Background:</i></b> Despite its approval in 1953, hydralazine hydrochloride continues to be used in the management of resistant hypertension, a condition frequently managed by nephrologists and other clinicians. Hydralazine hydrochloride undergoes metabolism by the N-acetyltransferase 2 (NAT2) enzyme. NAT2 is highly polymorphic as approximately 50% of the general population are slow acetylators. In this review, we first evaluate the link between NAT2 genotype and phenotype. We then assess the evidence available for genotype-guided therapy of hydralazine, specifically addressing associations of NAT2 acetylator status with hydralazine pharmacokinetics, antihypertensive efficacy, and toxicity. <b><i>Summary:</i></b> There is a critical need to use hydralazine in some patients with resistant hypertension. Available evidence supports a significant link between genotype and NAT2 enzyme activity as 29 studies were identified with an overall concordance between genotype and phenotype of 92%. The literature also supports an association between acetylator status and hydralazine concentration, as fourteen of fifteen identified studies revealed significant relationships with a consistent direction of effect. Although fewer studies are available to directly link acetylator status with hydralazine antihypertensive efficacy, the evidence from this smaller set of studies is significant in 7 of 9 studies identified. Finally, 5 studies were identified which support the association of acetylator status with hydralazine-induced lupus. Clinicians should maintain vigilance when prescribing maximum doses of hydralazine. <b><i>Key Messages:</i></b> NAT2 slow acetylator status predicts increased hydralazine levels, which may lead to increased efficacy and adverse effects. Caution should be exercised in slow acetylators with total daily hydralazine doses of 200 mg or more. Fast acetylators are at risk for inefficacy at lower doses of hydralazine. With appropriate guidance on the usage of <i>NAT2</i> genotype, clinicians can adopt a personalized approach to hydralazine dosing and prescription, enabling more efficient and safe treatment of resistant hypertension.

Acetylator status and its relationship to breast cancer and other diseases of the breast

1987 ◽  
Vol 23 (11) ◽  
pp. 1701-1706 ◽  
Author(s):  
P.A. Philip ◽  
H.J. Rogers ◽  
R.R. Millis ◽  
R.D. Rubens ◽  
R.A. Cartwright
Keyword(s):  
Breast Cancer ◽  
Acetylator Status

scholarly journals Acetylator status and diabetic neuropathy

Diabetologia ◽  
1982 ◽  
Vol 22 (6) ◽  
pp. 441-444 ◽  
Author(s):  
G. M. Shenfield ◽  
V. J. McCann ◽  
R. Tjokresetio
Keyword(s):  
Diabetic Neuropathy ◽  
Acetylator Status
Sign in / Sign up

Export Citation Format

Share Document